JP2025113267A5 - - Google Patents
Info
- Publication number
- JP2025113267A5 JP2025113267A5 JP2025071796A JP2025071796A JP2025113267A5 JP 2025113267 A5 JP2025113267 A5 JP 2025113267A5 JP 2025071796 A JP2025071796 A JP 2025071796A JP 2025071796 A JP2025071796 A JP 2025071796A JP 2025113267 A5 JP2025113267 A5 JP 2025113267A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306241.3A EP3628735A1 (en) | 2018-09-25 | 2018-09-25 | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
| EP18306241.3 | 2018-09-25 | ||
| JP2021540927A JP7757184B2 (ja) | 2018-09-25 | 2019-09-24 | シャルコー・マリー・トゥース１ａ病の治療のための、ｐｍｐ２２を標的とするアンチセンスｒｎａ |
| PCT/EP2019/075736 WO2020064749A1 (en) | 2018-09-25 | 2019-09-24 | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540927A Division JP7757184B2 (ja) | 2018-09-25 | 2019-09-24 | シャルコー・マリー・トゥース１ａ病の治療のための、ｐｍｐ２２を標的とするアンチセンスｒｎａ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025113267A JP2025113267A (ja) | 2025-08-01 |
| JP2025113267A5 true JP2025113267A5 (enExample) | 2025-10-22 |
Family
ID=63762431
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540927A Active JP7757184B2 (ja) | 2018-09-25 | 2019-09-24 | シャルコー・マリー・トゥース１ａ病の治療のための、ｐｍｐ２２を標的とするアンチセンスｒｎａ |
| JP2025071796A Pending JP2025113267A (ja) | 2018-09-25 | 2025-04-23 | シャルコー・マリー・トゥース１ａ病の治療のための、ｐｍｐ２２を標的とするアンチセンスｒｎａ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540927A Active JP7757184B2 (ja) | 2018-09-25 | 2019-09-24 | シャルコー・マリー・トゥース１ａ病の治療のための、ｐｍｐ２２を標的とするアンチセンスｒｎａ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11939577B2 (enExample) |
| EP (2) | EP3628735A1 (enExample) |
| JP (2) | JP7757184B2 (enExample) |
| AU (1) | AU2019350357B2 (enExample) |
| CA (1) | CA3112870A1 (enExample) |
| WO (1) | WO2020064749A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021184021A1 (en) * | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| US20230374519A1 (en) * | 2020-06-19 | 2023-11-23 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating pmp22 |
| IL303308A (en) * | 2020-12-01 | 2023-07-01 | Res Inst Nationwide Childrens Hospital | Products and methods for inhibiting the expression of myelin protein kp-22 |
| WO2023012165A1 (en) | 2021-08-02 | 2023-02-09 | Universite De Montpellier | Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22 |
| US20240318179A1 (en) * | 2021-10-22 | 2024-09-26 | Murdoch University | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| CA3235392A1 (en) | 2021-11-18 | 2023-05-25 | Novartis Ag | Compounds targeting pmp22 for the treatment of charcot-marie-tooth disease |
| WO2025242147A1 (zh) * | 2024-05-21 | 2025-11-27 | 北京安龙生物医药有限公司 | 靶向外周髓鞘蛋白-22基因的寡核苷酸及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2465534T3 (en) * | 2004-06-10 | 2017-07-03 | Omeros Corp | Method for treating conditions associated with MASP-2-dependent complement activation |
| FR2874016B1 (fr) | 2004-06-30 | 2006-11-24 | Centre Nat Rech Scient Cnrse | Nanoparticules de derives de la gemcitabine |
| WO2011005786A2 (en) * | 2009-07-06 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for enhancing production of a biological product |
| KR20220044616A (ko) * | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| US9970001B2 (en) * | 2014-06-05 | 2018-05-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease design |
| EP3169776B1 (en) * | 2014-07-14 | 2025-09-03 | The Regents of The University of California | Crispr/cas transcriptional modulation |
| US20170196954A1 (en) | 2014-07-15 | 2017-07-13 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| CA3013797A1 (en) * | 2016-03-09 | 2017-09-14 | Ionis Pharmaceuticals, Inc. | Methods and compositions for inhibiting pmp22 expression |
| MX385732B (es) | 2016-06-01 | 2025-03-18 | Infectious Disease Res Inst | Partículas de nanoalumbre que contienen un agente de dimensionamiento. |
| KR101872105B1 (ko) * | 2016-09-05 | 2018-06-27 | 사회복지법인 삼성생명공익재단 | 샤르코 마리 투스병 치료용 약학 조성물 |
| RU2022105597A (ru) * | 2016-11-14 | 2022-04-04 | Тулджен Инкорпорейтед | Искусственно созданная система управления функцией шк |
-
2018
- 2018-09-25 EP EP18306241.3A patent/EP3628735A1/en not_active Withdrawn
-
2019
- 2019-09-24 JP JP2021540927A patent/JP7757184B2/ja active Active
- 2019-09-24 CA CA3112870A patent/CA3112870A1/en active Pending
- 2019-09-24 WO PCT/EP2019/075736 patent/WO2020064749A1/en not_active Ceased
- 2019-09-24 EP EP19770132.9A patent/EP3856906A1/en active Pending
- 2019-09-24 AU AU2019350357A patent/AU2019350357B2/en active Active
- 2019-09-24 US US17/279,206 patent/US11939577B2/en active Active
-
2025
- 2025-04-23 JP JP2025071796A patent/JP2025113267A/ja active Pending